Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use CABENUVA safely and effectively. See full prescribing information for CABENUVA. CABENUVA (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular useInitial U.S. Approval: 2021
Medication labelWhy this: Advisory · dailymed-prescription
CABENUVA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine [see Microbiology (12.4), Clinical Studies (14.1)].
- generic_name
- cabotegravir and rilpivirine
- brand_name
- cabotegravir, rilpivirine
- product_names
- cabotegravir and rilpivirine, cabotegravir, rilpivirine
- ndc
- 49702-253, 49702-240, 49702-245, 49702-238, 49702-249, 49702-243, 49702-253-15, 49702-245-01, 49702-249-02, 49702-240-15, 49702-238-01, 49702-243-02, 49702-266, 49702-266-63, 49702-238-64, 49702-243-61
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en